Autolus Therapeutics (AUTL) Stock Rating Reaffirmed by HC Wainwright

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Friday. They currently have a $45.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 41.73% from the company’s previous close.

The analysts wrote, “We envision upside to our target if the upcoming data reflect the anticipated advantages of Autolus’ CAR T assets. Our $45 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model. Our DCF is based on: beta of 1.45, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2027.””

Several other analysts also recently issued reports on AUTL. Jefferies Financial Group initiated coverage on shares of Autolus Therapeutics in a research report on Tuesday, July 17th. They issued a “buy” rating and a $37.00 price target for the company. William Blair assumed coverage on shares of Autolus Therapeutics in a report on Tuesday, July 17th. They set an “outperform” rating on the stock. Wells Fargo & Co assumed coverage on shares of Autolus Therapeutics in a report on Tuesday, July 17th. They set an “outperform” rating and a $38.00 price objective on the stock. Finally, Goldman Sachs Group assumed coverage on shares of Autolus Therapeutics in a report on Thursday, July 26th. They set a “neutral” rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $40.00.

NASDAQ AUTL opened at $31.75 on Friday. Autolus Therapeutics has a 12-month low of $19.17 and a 12-month high of $34.22.

Institutional investors and hedge funds have recently bought and sold shares of the business. Jennison Associates LLC purchased a new position in Autolus Therapeutics during the 2nd quarter worth $3,168,000. Janus Henderson Group PLC purchased a new position in Autolus Therapeutics during the 2nd quarter worth $498,000. Hermes Investment Management Ltd. purchased a new position in Autolus Therapeutics during the 2nd quarter worth $1,248,000. Aquilo Capital Management LLC purchased a new position in Autolus Therapeutics during the 2nd quarter worth $4,018,000. Finally, Essex Investment Management Co. LLC purchased a new position in Autolus Therapeutics during the 2nd quarter worth $1,011,000. 21.17% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Read More: How can you know how many shares are floating?

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply